In the Claims:

Claim 48 has been canceled.

Please amend Claims 39-44 as follows:

- 39. (Currently amended) An isolated polypeptide having at least 80% amino adid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292);
- (b) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292); or
- (d) the amine-acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide; or
- the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209439.

 wherein said polypeptide is capable of inducing an immune or inflammatory response.
- 40. (Currently amended) The isolated polypeptide of Claim 39 having at least 85% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292);
- (b) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide;
- (e)(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292); or
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209439.

Am indiment and Response to Office Action (dated February 25, 2003) Application Serial No. 09/905,056 Att rney's Dicket No. 39780-1618P2C44

wherein said polypeptide is capable of inducing an immune or inflammatory response.

- 41. (Currently amended) The isolated polypeptide of Claim 39 having at least 90% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292);
- (b) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292); or
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEO ID NO:292), lacking its associated signal peptide; or
- the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209439, wherein said polypeptide is capable of inducing an immune or inflammatory response.
- 42. (Currently amended) The isolated polypeptide of Claim 39 having at least 95% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292);
- (b) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292); or
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide; or
- the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209439, wherein said polypeptide is capable of inducing an immune or inflammatory response.

Amendm nt and Response to Office Action (dated February 25, 2003) Application Serial No. 09/905,056 Attorney's Docket No. 39780-1618P2C44

- 43. (Currently amended) The isolated polypeptide of Claim 39 having at least 99% amino acid sequence identity to:
- (a) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO 292);
- (b) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide,
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292); or
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide; or
- the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209439,

 wherein said polypeptide is capable of inducing an immune or inflammatory response.
 - 44. (Currently amended) An isolated polypeptide comprising:
 - (a) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292);
 - (b) the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide;
 - the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292); or
 - (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide; or
 - (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209439.
 - 45. (Previously added) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292).

Amendment and Response to Office Action (dated February 25, 2003)
Application Serial No. 09/905,056
Attorney's Docket No. 39780-1518P2C44

- 46. (Previously added) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide shown in Figure 104 (SEQ ID NO:292), lacking its associated signal peptide.
- 47. (Previously added) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 104 (SEQ ID NO:292).
- 48. Canceled.
- 49. (Previously added) The isolated polypeptide of Claim 44 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209439.
- 50. (Previously added) A chimeric polypeptide comprising a polypeptide according to Claim 39 fused to a heterologous polypeptide.
- 51. (Previously added) The chimeric polypeptide of Claim 50, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.